C50-C50 C51-C58
Conditions
Interventions
Group 1: Randomised arm: participants will be randomly allocated into the intervention group (usual care + complementary and alternative medicine(CAM)) and the control group (usual care). Participants
Sponsors
Abteilung Allgemeinmedizin und VersorgungsforschungUniversitätsklinikum Heidelberg
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: All female patients diagnosed with gynaecologic cancer and scheduled for a new treatment of chemotherapy will be invited for the study.
Exclusion criteria
Exclusion criteria: < 18 years, gender: male, insufficient knowledge of German
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Health-related quality of life: measured with the EORTC-QLQ-C30 at time points T1, T2, T3, T4. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes: Nausea (MAT), fatigue (FACIT-F), pain (VAS), anxiety/depression (PHQ-9), social support (F-SozU-K14), self-efficacy (SES6G), patient competence (FEPK 2-57), spiritual wellbeing (Sp-REUK-15), patient satisfaction (EORTC-QLQ-PATSAT32) and health economic data (Mannheimer Modul RV) will be analysed at T1 (start of chemotherapy), T2 (midline), T3 (end of Treatment) and T4 (6 months after Treatment). Quality of life of patients' caregivers (WHOQOL-BREF) will be collected at time-points T1, T3, and T4. | — |
Countries
Germany
Contacts
Public ContactStefanie Joos
Abteilung Allgemeinmedizin und Versorgungsforschung
Outcome results
None listed